Entero Therapeutics (NASDAQ:ENTO) Shares Down 3.4% – Should You Sell?

Entero Therapeutics, Inc. (NASDAQ:ENTO) shares dropped 3.4% on Friday . The stock traded as low as $2.21 and last traded at $2.27. Approximately 70,525 shares traded hands during trading, a decline of 97% from the average daily volume of 2,798,922 shares. The stock had previously closed at $2.35.

Entero Therapeutics Price Performance

The firm’s 50-day simple moving average is $2.37 and its two-hundred day simple moving average is $3.14. The company has a market capitalization of $3.60 million, a price-to-earnings ratio of -1.34 and a beta of 1.19.

Institutional Trading of Entero Therapeutics

An institutional investor recently bought a new position in Entero Therapeutics stock. Virtu Financial LLC purchased a new stake in Entero Therapeutics, Inc. (NASDAQ:ENTO) during the 3rd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor purchased 11,829 shares of the company’s stock, valued at approximately $59,000. Virtu Financial LLC owned approximately 0.74% of Entero Therapeutics at the end of the most recent reporting period. Institutional investors and hedge funds own 12.30% of the company’s stock.

Entero Therapeutics Company Profile

Entero Therapeutics, Inc (NASDAQ: ENTO) is a clinical‐stage specialty pharmaceutical company dedicated to developing innovative therapies for patients suffering from rare and debilitating gastrointestinal (GI) disorders. The company leverages targeted delivery technologies designed to localize therapeutic molecules directly to affected regions of the GI tract, aiming to enhance efficacy while minimizing systemic exposure. Entero’s research and development efforts focus on addressing chronic conditions with significant unmet medical needs, including malabsorption syndromes and motility‐related GI diseases.

Entero’s pipeline features multiple lead candidates in varying stages of clinical development.